Lung Cancer Clincial Trials

MERCK (3475-799)

A Phase II Trial of Pembrolizumab in Combination with Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (KEYNOTE-799)

Learn more.


MERCK (3475-671)

A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer

Learn more.


MERCK (7902-007)

A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)

Learn more.


A151216 (ALCHEMIST)

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). Testing for EGFR, ALK, PD-L1. Sponsor will pay for testing if no local results available.

Learn more.


A081105 (Sub-study of Alchemist)

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Learn more.


E4512 (Sub-study of Alchemist)

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Learn more.


LungMap

A Biomarker-Driven Master Protocol for Previously Treated Non-Small Cell Lung Cancer (LUNG-MAP)

Learn more.


CC003

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer

Learn more.


A08110 (sub-study of ALCHEMIST)

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Learn more.


ECOG E4512

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Learn more.


S1900A (Sub-study of LungMAP)

Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Learn more.


S1800A (Sub-study of LungMAP)

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Learn more.


S1400F (Sub-study of LungMAP)

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

Learn more.


AstraZeneca PACIFIC4

Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients (PACIFIC-4)

Learn more.